Heart Failure Devices Global Market - Forecast To 2029

Publishing Date : March, 2023
Report Code : HCMD0177
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

 

Heart Failure Devices (HFD) Heart failure occurs when the heart muscle does not pump blood as well as it should, when this happens blood often backs up and causes shortness of breath. In some people, the heart has difficulty pumping enough blood to support other organs in the body. Others may have a hardening and stiffening of the heart muscle itself, which blocks or reduces blood flow to the heart.

According to IQ4I analysis, the heart failure devices global market expected to grow at high single-digit CAGR from 2022 to 2029 to reach $38,879.9 million by 2029. Factors such as increasing incidence of heart failure diseases, technological advancement in heart failure devices, rising geriatric population, and favorable reimbursement are the drivers, vast pipeline products, increase in funding and approvals are the opportunities. Adverse events and complications with the implantation of heart failure devices, the high cost of the devices, and the lack of trained professionals are the restraints, whereas, stringent regulatory guidelines and the availability of alternative products are the threats.

The heart failure devices global market is segmented based on products, end-users, surgery and geography. The heart failure devices market based on products is segmented as cardiac rhythm products, cardiac assist devices (CAD), structural heart devices (SHD), ECMO and others (modulation devices). Among them, the structural heart device segment commands the largest revenue in 2022 and it is expected to grow at double digit CAGR from 2022 to 2029.

The cardiac rhythm products based on product type is segmented into Implantable Cardioverter Defibrillators (ICD), pacemakers and Cardiac Resynchronization Therapy (CRT) devices. Among them, the ICD segment commanded the largest revenue n 2022 and it is expected to grow at mid single-digit CAGR from 2022 to 2029. The CRT segment is expected to grow at mid single digit CAGR from 2022 to 2029. The Implantable Cardioverter Defibrillators (ICDs) are further segmented into Single and dual-chamber ICDs, among which, dual-chamber devices accounted for the largest revenue in 2022 and is expected to grow at mid single digit CAGR from 2022 to 2029. The pacemakers are segmented into single and dual-chamber pacemakers, among which, dual chamber accounted for the largest revenue in 2022 and is expected to grow at low single digit CAGR from 2022 to 2029.  The CRT global market is expected to grow at mid single digit CAGR from 2022 to 2029. The CRT is further segmented into CRT-P and CRT-D; among which, CRT-D accounted for the largest revenue in 2022 and is expected grow at mid single digit CAGR from 2022 to 2029.

Cardiac assist devices based on products are segmented into Ventricular Assist Devices (VAD), Intra aortic balloon pumps (IABP) and Total Artificial Heart (TAH). The Ventricular Assist Devices (VAD) commanded the largest revenue of the Cardiac assist devices global market based on the product in 2022 and is expected to grow at double digit CAGR from 2022 to 2029. VAD based on product type is further sub-segmented into Left-VAD (LVAD), Right-VAD (R-VAD), and Bi-VAD, among which, LVAD has the largest revenue in 2022 and is expected to grow at double digit CAGR from 2022 to 2029.

The structural heart devices are segmented into repair devices and replacement devices, among which, the replacement device segment accounted for the largest revenue in 2022 and is expected to grow at double digit CAGR from 2022 to 2029. Repair devices are expected to grow at early teen CAGR from 2022 to 2029. The repair devices are segmented into annuloplasty, valvuloplasty, occluders, Transcatheter Mitral Valve Repair (TMVr) and others (Chrodal replacement, TTVR, Ventricular restoration system, & Shunt), among these, occluders segment accounted for the largest revenue in 2022 and is expected to grow at a mid teen CAGR from 2022 to 2029 The TMVr segment is expected to grow at mid teen CAGR from 2022 to 2029. The heart valve replacement techniques are broadly classified into surgical and transcatheter-based techniques, among which the transcatheter valve segment accounted for the largest revenue in 2022 and is expected to grow strong at double digit CAGR from 2022 to 2029. The surgical technique is further segmented into mechanical valves and tissue valves, among which, the tissue heart valve segment accounted for the largest revenue in 2022. The transcatheter valve replacement devices global market is segmented into Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral Valve Replacement (TMVR) and Transcatheter Pulmonary Valve Replacement (TPVR), among which TAVR segment occupies the largest share in 2022 and TMVR device segment is expected to grow at a high double digit CAGR from 2022 to 2029.

Heart Failure Devices global market based on surgery is segmented into open surgery, minimally invasive surgery and robotic surgery, among these, the open surgery segment accounted for the largest revenue in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029. Robotic surgery is the fastest-growing segment and is expected to grow at high teen CAGR from 2022 to 2029.

Heart Failure Devices global market based on end-users is segmented into hospitals, ambulatory surgical centers (ASC) and others (academics & research institutes and OBL). Among end-users, the hospital segment accounted for the largest revenue in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029. The ambulatory surgical center is the fastest-growing segment and is expected to grow at early teen CAGR from 2022 to 2029.

The heart failure devices market based on region is segmented as North America (U.S. and the Rest of North America), Europe (Germany, France, Italy, and the Rest of Europe), Asia-Pacific (Japan, China, India and the Rest of APAC), and the Rest of the world (Brazil, Rest of LATAM and the Middle East & Africa). North America holds the largest revenue in 2022 and it is expected to grow at high single digit CAGR from 2022 to 2029 mainly due to the increasing prevalence of structural heart diseases in the region, persistently elevating geriatric population burdened with various kinds of valvular diseases, increasing preference and adoption of the patient population there for technologically advanced and minimally invasive therapeutic products, availability of advanced imaging and better patient screening programs and increasing investments on research activities for developing innovative and technologically advanced products.

The Asia-Pacific is the fastest-growing region and is expected to grow in double digit CAGR from 2022 to 2029 due to the high structural heart disease burden in the region, increasing geriatric population, increasing demand for better healthcare facilities, increasing penetration of reimbursement schemes in developing countries, increasing demand for highly efficient and minimally invasive products from the value-centric patient population, growing economies of the region, availability of various kinds of heart failure treatment products, increasing patient awareness of these products and increasing medical tourism prospects of the region.

The heart failure devices global market is a consolidated market with the top 8 players occupying XX% of the market hence all the existing players in this market are involved in developing new and advanced therapeutics to maintain their market shares. Some of the major players in the heart failure devices market include Medtronic PLC (Ireland), Abbott Laboratories (U.S.), Edwards Lifesciences Corporation (U.S.), Boston Scientific Corporation (U.S.), Abiomed (U.S.), Biotronik (Germany), Getinge (Sweden) and MicroPort (China).

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING INCIDENCE OF HEART FAILURE
        • 3.3.1.2     TECHNOLOGICAL ADVANCEMENTS IN HEART FAILURE DEVICES
        • 3.3.1.3     RISING GERIATRIC POPULATION
        • 3.3.1.4     VAST PIPELINE PRODUCTS
        • 3.3.1.5     INCREASE IN PRODUCT APPROVALS
        • 3.3.1.6     INCREASE IN FUNDING
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     ADVERSE EVENTS AND COMPLICATIONS WITH THE IMPLANTATION OF HEART FAILURE DEVICES
        • 3.3.2.2     HIGH COST OF THE DEVICES
        • 3.3.2.3     LACK OF SKILLED AND TRAINED PROFESSIONALS
        • 3.3.2.4     STRINGENT REGULATORY GUIDELINES
        • 3.3.2.5     AVAILABILITY OF ALTERNATIVE PRODUCTS
        • 3.3.2.6     INCREASING PRODUCT RECALLS
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     COMMERCIALIZATION REGULATORY AFFAIRS
      • 3.4.2     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
        • 3.4.2.1     ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM
        • 3.4.2.2     ISO 14644-1 CLEANROOM STANDARDS
        • 3.4.2.3     ISO 13485 MEDICAL DEVICES
        • 3.4.2.4     ISO 10993 BIOLOGICAL EVALUATION OF MEDICAL DEVICES
        • 3.4.2.5     ISO 14971: RISK MANAGEMENT OF MEDICAL DEVICES
        • 3.4.2.6     ISO 5840: HEART VALVE VALIDATION
        • 3.4.2.7     ISO 14708-5: ACTIVE IMPLANTABLE MEDICAL DEVICES - PART 5: CIRCULATORY SUPPORT DEVICES
        • 3.4.2.8     IEC 60601-1 MEDICAL ELECTRICAL EQUIPMENT STANDARD
        • 3.4.2.9     IEC 60601-1-11 HOME CARE SAFETY
        • 3.4.2.10     ASTM INTERNATIONAL STANDARDS
      • 3.4.3     U.S.
      • 3.4.4     CANADA
      • 3.4.5     EUROPE
      • 3.4.6     CHINA
      • 3.4.7     JAPAN
      • 3.4.8     INDIA
    • 3.5     CLINICAL TRIALS DATA
    • 3.6     REIMBURSEMENT SCENARIO
      • 3.6.1     REIMBURSEMENT TABLE
        • 3.6.1.1     STRUCTURAL HEART DEVICE REIMBURSEMENT
        • 3.6.1.2     RHYTHM MANAGEMENT DEVICE IMPLANT PROCEDURES
        • 3.6.1.3     SURGICAL VALVE REPAIR AND REPLACEMENT PROCEDURES
        • 3.6.1.4     VENTRICULAR ASSIST DEVICE REIMBURSEMENT
        • 3.6.1.5     CAD PHYSICIAN REIMBURSEMENT
    • 3.7     PORTER'S FIVE FORCE ANALYSIS
      • 3.7.1     THREAT OF NEW ENTRANTS
      • 3.7.2     THREAT OF SUBSTITUTES
      • 3.7.3     BARGAINING POWER OF SUPPLIERS
      • 3.7.4     BARGAINING POWER OF BUYERS
      • 3.7.5     COMPETITIVE RIVALRY
    • 3.8     PATENT ANALYSIS
    • 3.9     TECHNOLOGICAL ADVANCEMENTS
      • 3.9.1     BIONIC PACEMAKER
      • 3.9.2     PULSE VAD
      • 3.9.3     VADOVATIONS CARDIAC ASSIST SYSTEM
      • 3.9.4     TOTAL ARTIFICIAL HEART (TAH)
      • 3.9.5     FULLY IMPLANTED BIORESORBABLE CARDIAC PACEMAKERS WITHOUT LEADS AND BATTERIES
      • 3.9.6     INTERATRIAL SHUNT
      • 3.9.7     VAGUS NERVE STIMULATION
      • 3.9.8     ELECTRICAL MICROCURRENT THERAPY
      • 3.9.9     CONTRABAND
    • 3.10     SUPPLY CHAIN ANALYSIS
    • 3.11     FUNDING SCENARIO
    • 3.12     PRODUCT APPROVALS
    • 3.13     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.13.1     HEARTFAILURE DEVICES GLOBAL MARKET SHARE ANALYSIS
      • 3.13.2     VENTRICULAR ASSIST DEVICES GLOBAL MARKET SHARE ANALYSIS
      • 3.13.3     INTRA-AORTIC BALLOON PUMP (IABP) GLOBAL MARKET SHARE ANALYSIS
      • 3.13.4     CARDIAC RESYNCHRONIZATION THERAPY GLOBAL MARKET SHARE ANALYSIS
      • 3.13.5     IMPLANTABLE CARDIOVERTER DEFIBRILLATORS GLOBAL MARKET SHARE ANALYSIS
        • 3.13.5.1     SINGLE CHAMBER ICD
        • 3.13.5.2     DUAL CHAMBER ICD
      • 3.13.6     PACEMAKERS GLOBAL MARKET SHARE ANALYSIS
        • 3.13.6.1     SINGLE CHAMBER PACEMAKER
        • 3.13.6.2     DUAL CHAMBER PACEMAKER
      • 3.13.7     MARKET SHARE ANALYSIS OF ANNULOPLASTY REPAIR DEVICES BASED ON MAJOR PLAYERS
      • 3.13.8     MARKET SHARE ANALYSIS OF OCCLUDERS BASED ON MAJOR PLAYERS
      • 3.13.9     MARKET SHARE ANALYSIS OF MECHANICAL VALVE BASED ON MAJOR PLAYERS
    • 3.14     PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION
      • 3.14.1     U.S. PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS
      • 3.14.2     ITALY PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS
      • 3.14.3     GERMANY PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS
      • 3.14.4     FRANCE PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS
      • 3.14.5     JAPAN PERCUTANEOUS VENTRICULAR ASSIST DEVICE (PVAD) MARKET PENETRATION ANALYSIS
    • 3.15     INTRA-AORTIC BALLOON PUMP (IABP) TOTAL ADRESSABLE MARKET (TAM) & MARKET PENETRATION
      • 3.15.1     U.S. INTRA-AORTIC BALLOON PUMP (IABP) TOTAL ADDRESSABLE MARKET (TAM) & MARKET PENETRATION ANALYSIS
      • 3.15.2     ITALY INTRA-AORTIC BALLOON PUMP (IABP) TOTAL ADDRESSABLE MARKET (TAM) & MARKET PENETRATION ANALYSIS
      • 3.15.3     GERMANY INTRA-AORTIC BALLOON PUMP (IABP) TOTAL ADDRESSABLE MARKET (TAM) & MARKET PENETRATION ANALYSIS
      • 3.15.4     FRANCE INTRA-AORTIC BALLOON PUMP (IABP) TOTAL ADDRESSABLE MARKET (TAM) MARKET PENETRATION ANALYSIS
      • 3.15.5     JAPAN INTRA-AORTIC BALLOON PUMP (IABP) TOTAL ADDRESSABLE MARKET (TAM) & MARKET PENETRATION ANALYSIS
    • 3.16     STRUCTURAL HEART DEVICES TOTAL ADDRESSABLE MARKET (TAM), MARKET PENETRATION, PREVALENCE, AND NUMBER OF PROCEDURES PERFORMED
    • 3.17     BAROREFLEX ACTIVATION THERAPY (BAT) MARKET PENETRATION, PREVALENCE, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED
    • 3.18     CARDIAC ASSIST DEVICES NUMBER OF UNITS SOLD BASED ON REGION
      • 3.18.1     VENTRICULAR ASSIST DEVICES NUMBER OF UNITS SOLD BASED ON REGION
        • 3.18.1.1     VENTRICULAR ASSIST DEVICES (VAD) NUMBER OF UNITS SOLD
        • 3.18.1.2     PERCUTANEOUS VENTRICULAR ASSIST DEVICES NUMBER OF UNITS SOLD
      • 3.18.2     IABP DEVICES GLOBAL NUMBER OF UNITS SOLD BASED ON REGION
      • 3.18.3     TOTAL ARTIFICIAL HEART NUMBER OF UNITS BASED ON REGION
    • 3.19     STRUCTURAL HEART DEVICES NUMBER OF UNITS SOLD BASED ON REGION
    • 3.20     CARDIAC RHYTHM PRODUCTS NUMBER OF UNITS SOLD BASED ON REGION
    • 3.21     TAVR CENTERS
    • 3.22     STRUCTURAL HEART DEVICES COMPANY COMPARISON TABLE BASED ON PRODUCTS
      • 3.22.1     TRANSCATHETER HEART VALVE COMPANY COMPARISON TABLE BASED ON PRODUCT AND INDICATION
      • 3.22.2     OCCLUDERS COMPANY COMPARISON TABLE BASED ON PRODUCTS AND INDICATION
      • 3.22.3     VALVULOPLASTY COMPANY COMPARISON TABLE BASED ON PRODUCTS AND INDICATION
      • 3.22.4     ANNULOPLASTY COMPANY COMPARISON TABLE BASED ON PRODUCTS AND INDICATION
      • 3.22.5     MECHANICAL HEART VALVES COMPANY COMPARISON TABLE BASED ON PRODUCTS AND INDICATION
      • 3.22.6     TISSUE HEART VALVES COMPANY COMPARISON TABLE BASED ON PRODUCTS AND INDICATION
    • 3.23     REUSE OF PACEMAKERS AND ICDS
    • 3.24     TRICUSPID VALVE PIPELINE
      • 3.24.1     CURRENT TREATMENT OPTIONS FOR TR MANAGEMENT
      • 3.24.2     TRANSCATHETER TRICUSPID VALVE REPLACEMENT (TTVR)
        • 3.24.2.1     ORTHOTOPIC IMPLANTS PIPELINE
        • 3.24.2.2     HETEROTOPIC IMPLANTS PIPELINE
  • 4     HEART DEVICES GLOBAL MARKET, BASED ON PRODUCT
    • 4.1     INTRODUCTION
    • 4.2     CARDIAC RHYTHM PRODUCTS
      • 4.2.1     IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICDS)
      • 4.2.2     SINGLE-CHAMBER ICD
      • 4.2.3     DUAL-CHAMBER ICD
    • 4.3     PACEMAKER
      • 4.3.1     SINGLE-CHAMBER PACEMAKER
      • 4.3.2     DUAL-CHAMBER PACEMAKER
    • 4.4     CARDIAC RESYNCHRONIZATION THERAPY
      • 4.4.1     CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR (CRT-D)
      • 4.4.2     CARDIAC RESYNCHRONIZATION THERAPY PACEMAKERS (CRT-P)
    • 4.5     NEW YORK HEART CLASSIFICATION AND CARDIAC RHYTHM THERAPY CHOICE
    • 4.6     CARDIAC ASSIST DEVICE (CAD)
      • 4.6.1     VENTRICULAR ASSIST DEVICES (VAD)
      • 4.6.2     LEFT VENTRICULAR ASSIST DEVICES (LVAD)
      • 4.6.3     RIGHT VENTRICULAR ASSIST DEVICES (RVAD)
      • 4.6.4     BI-VENTRICULAR ASSIST DEVICES (BI-VAD)
      • 4.6.5     INTRA-AORTIC BALLOON PUMP (IABP)
      • 4.6.6     TOTAL ARTIFICIAL HEART (TAH)
    • 4.7     STRUCTURAL HEART DEVICES (SHD)
      • 4.7.1     REPAIR DEVICES
        • 4.7.1.1     ANNULOPLASTY REPAIR DEVICES
        • 4.7.1.2     VALVULOPLASTY
        • 4.7.1.3     OCCLUDERS
        • 4.7.1.4     TRANSCATHETER MITRAL VALVE REPAIR (TMVR) DEVICES
        • 4.7.1.5     OTHER STRUCTURAL HEART REPAIR DEVICES
      • 4.7.2     REPLACEMENT DEVICES
        • 4.7.2.1     SURGICAL VALVE REPLACEMENT DEVICES
          • 4.7.2.1.1     MECHANICAL HEART VALVES
          • 4.7.2.1.2     TISSUE HEART VALVES (BIOLOGICAL VALVES)
        • 4.7.2.2     TRANSCATHETER VALVE REPLACEMENT DEVICES
          • 4.7.2.2.1     TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)
          • 4.7.2.2.2     TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR)
          • 4.7.2.2.3     TRANSCATHETER PULMONARY VALVE REPLACEMENT (TPVR)
    • 4.8     EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
    • 4.9     OTHERS (BAT AND CCM TECHNOLOGY)
      • 4.9.1     BAROREFLEX ACTIVATION THERAPY
      • 4.9.2     CARDIAC CONTRACTILITY MODULATION (CCM)
  • 5     HEART FAILURE DEVICES GLOBAL MARKET, BASED ON SURGERY
    • 5.1     INTRODUCTION
    • 5.1     ROBOTIC SURGERY
    • 5.2     OPEN HEART SURGERY
    • 5.3     MINIMALLY INVASIVE SURGERY
  • 6     HEART FAILURE DEVICES GLOBAL MARKET, BASED ON END-USERS
    • 6.1     INTRODUCTION
      • 6.1.1     HOSPITALS
      • 6.1.2     AMBULATORY SURGICAL CENTERS (ASCS)
      • 6.1.3     OTHER END-USERS
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     REST OF NORTH AMERICA
    • 7.3     EUROPE
      • 7.3.1     GERMANY
      • 7.3.2     FRANCE
      • 7.3.3     ITALY
      • 7.3.4     REST OF EUROPE
    • 7.4     APAC
      • 7.4.1     JAPAN
      • 7.4.2     CHINA
      • 7.4.3     INDIA
      • 7.4.4     REST OF APAC
    • 7.5     REST OF THE WORLD
      • 7.5.1     BRAZIL
      • 7.5.2     REST OF LATAM
      • 7.5.3     MIDDLE EAST AND AFRICA
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     PRODUCT APPROVALS
    • 8.3     ACQUISITIONS
    • 8.4     NEW PRODUCT LAUNCH
    • 8.5     INVESTMENT AND FUNDING
    • 8.6     OTHER DEVELOPMENTS
  • 9     MAJOR COMPANIES
    • 9.1     ABBOTT LABORATORIES
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     ABIOMED
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     BIOTRONIK SE & CO. KG
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     BOSTON SCIENTIFIC CORPORATION
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     CORCYM
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     EDWARDS LIFESCIENCES CORPORATION
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     GETINGE
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     MEDTRONIC, PLC
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     MICROPORT SCIENTIFIC CORPORATION
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.10     TELEFLEX INCORPORATED
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     HEART FAILURE DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 2     VAD NUMBER OF UNITS SOLD, BASED ON REGION, (2022) (NO'S)
      • TABLE 3     PERCUTANEOUS VAD NUMBER OF UNITS SOLD, BASED ON REGION, (2021-2029) (NO'S)
      • TABLE 4     IABP NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO'S)
      • TABLE 5     TOTAL ARTIFICIAL HEART NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NO'S)
      • TABLE 6     HEART FAILURE DEVICES (HFD) GLOBAL MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
      • TABLE 7     CARDIAC RHYTHM PRODUCTS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 8     CARDIAC RHYTHM PRODUCTS GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 9     ICD GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 10     ICD GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 11     SINGLE-CHAMBER ICD GLOBAL MARKET REVENUE, BAESD ON REGION, (2021-2029) ($MN)
      • TABLE 12     DUAL-CHAMBER ICD GLOBAL MARKET REVENUE, BAESD ON REGION, (2021-2029) ($MN)
      • TABLE 13     PACEMAKER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 14     PACEMAKER GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 15     SINGLE-CHAMBER PACEMAKER GLOBAL MARKET REVENUE, BAESD ON REGION, (2021-2029) ($MN)
      • TABLE 16     DUAL-CHAMBER PACEMAKER GLOBAL MARKET REVENUE, BAESD ON REGION, (2021-2029) ($MN)
      • TABLE 17     CRT GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 18     CRT GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 19     CRT-D GLOBAL MARKET REVENUE, BAESD ON REGION, (2021-2029) ($MN)
      • TABLE 20     CRT-P GLOBAL MARKET REVENUE, BAESD ON REGION, (2021-2029) ($MN)
      • TABLE 21     CAD GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 22     CAD GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 23     VAD GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 24     VAD GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 25     LVAD GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 26     RVAD GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 27     BI-VAD GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 28     IABP GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 29     TAH GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 30     STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 31     STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 32     REPAIR DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 33     REPAIR DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 34     ANNULOPLASTY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 35     VALVULOPLASTY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 36     OCCLUDERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 37     LIST OF APPROVED TMVR PRODUCTS CURRENTLY AVAILABLE IN THE MARKET
      • TABLE 38     PIPELINE OF TMVR PRODUCTS
      • TABLE 39     TMVR GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 40     OTHER REPAIR DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 41     REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 42     REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 43     SURGICAL VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 44     SURGICAL VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 45     MECHANICAL HEART VALVES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 46     TISSUE HEART VALVES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 47     TRANSCATHETER VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 48     TRANSCATHETER VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 49     LIST OF APPROVED TAVR PRODUCTS CURRENTLY AVAILABLE IN THE MARKET
      • TABLE 50     PIPELINE OF TAVR PRODUCTS
      • TABLE 51     TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 52     LIST OF APPROVED TMVR PRODUCTS CURRENTLY AVAILABLE IN THE MARKET
      • TABLE 53     PIPELINE OF TMVR PRODUCTS
      • TABLE 54     TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 55     LIST OF APPROVED TPVR PRODUCTS CURRENTLY AVAILABLE IN THE MARKET
      • TABLE 56     PIPELINE OF TPVR PRODUCTS
      • TABLE 57     TRANSCATHETER PULMONARY VALVE REPLACEMENT (TPVR) GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 58     ECMO GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 59     OTHER HEART FAILURE DEVICES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 60     HEART FAILURE DEVICES GLOBAL MARKET REVENUE, BASED ON SURGERY (2021-2029) ($MN)
      • TABLE 61     ROBOTIC SURGERY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 62     OPEN SURGERY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 63     MINIMALLY INVASIVE SURGERY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • TABLE 64     HEART FAILURE DEVICES GLOBAL MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 65     HOSPITALS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 66     AMBULATORY SURGICAL CENTERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 67     OTHER END-USERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 68     HEART FAILURE DEVICES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 69     NORTH AMERICA HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD (2022)
      • TABLE 70     NORTH AMERICA HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN)
      • TABLE 71     NORTH AMERICA CARDIAC RHYTHM PRODUCTS MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 72     NORTH AMERICA CRT MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 73     NORTH AMERICA ICD MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 74     NORTH AMERICA PACEMAKER MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 75     NORTH AMERICA CAD MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 76     NORTH AMERICA VAD MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 77     NORTH AMERICA SHD MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 78     NORTH AMERICA REPAIR DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 79     NORTH AMERICA REPLACEMENT DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 80     NORTH AMERICA SURGICAL VALVE MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 81     NORTH AMERICA TRANSCATHETER VALVE MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 82     NORTH AMERICA HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 83     NORTH AMERICA HEART FAILURE DEVICES MARKET REVENUE, BASED ON SURGERY, (2021-2029) ($MN)
      • TABLE 84     NORTH AMERICA HEART FAILURE DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 85     U.S. SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD (2022)
      • TABLE 86     REST OF N.A. SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD(2022)
      • TABLE 87     EUROPE HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD (2022)
      • TABLE 88     EUROPE HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
      • TABLE 89     EUROPE CARDIAC RHYTHM PRODUCTS MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 90     EUROPE CRT MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 91     EUROPE ICD MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 92     EUROPE PACEMAKER MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 93     EUROPE CAD MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 94     EUROPE VAD MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 95     EUROPE SHD MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 96     EUROPE REPAIR DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 97     EUROPE REPLACEMENT DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 98     EUROPE SURGICAL VALVE MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 99     EUROPE TRANSCATHETER VALVE MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 100     EUROPE HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 101     EUROPE HEART FAILURE DEVICES MARKET REVENUE, BASED ON SURGERY, (2021-2029) ($MN)
      • TABLE 102     EUROPE HEART FAILURE DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 103     GERMANY SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD(2022)
      • TABLE 104     FRANCE SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD(2022)
      • TABLE 105     ITALY SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD(2022)
      • TABLE 106     THE REST OF EUROPE SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD(2022)
      • TABLE 107     APAC HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
      • TABLE 108     APAC CARDIAC RHYTHM PRODUCTS MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 109     APAC CRT MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 110     APAC ICD MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 111     APAC PACEMAKER MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 112     APAC CAD MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 113     APAC VAD MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 114     APAC SHD MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 115     APAC REPAIR DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 116     APAC REPLACEMENT DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 117     APAC SURGICAL VALVE MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 118     APAC TRANSCATHETER VALVE MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 119     APAC HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 120     APAC HEART FAILURE DEVICES MARKET REVENUE, BASED ON SURGERY, (2021-2029) ($MN)
      • TABLE 121     ASIA-PACIFIC HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD(2022)
      • TABLE 122     APAC HEART FAILURE DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 123     JAPAN SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD(2022)
      • TABLE 124     CHINA SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD(2022)
      • TABLE 125     INDIA SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD(2022)
      • TABLE 126     REST OF APAC SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD(2022)
      • TABLE 127     ROW HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
      • TABLE 128     ROW CARDIAC RHYTHM PRODUCTS MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 129     ROW CRT MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 130     ROW ICD MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 131     ROW PACEMAKER MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 132     ROW CAD MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 133     ROW VAD MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 134     ROW SHD MARKET REVENUE, BASED ON PRODUCTS (2021-2029) ($MN)
      • TABLE 135     ROW REPAIR DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 136     ROW REPLACEMENT DEVICES MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 137     ROW SURGICAL VALVE MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 138     ROW TRANSCATHETER VALVE MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 139     ROW HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 140     ROW HEART FAILURE DEVICES MARKET REVENUE, BASED ON SURGERY, (2021-2029) ($MN)
      • TABLE 141     ROW HEART FAILURE DEVICES MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 142     ROW HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD(2022)
      • TABLE 143     BRAZIL SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD(2022)
      • TABLE 144     REST OF LATAM SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD(2022)
      • TABLE 145     MIDDLE EAST AND AFRICA SELECTED HEART FAILURE DEVICES AVERAGE SELLING PRICE (ASP) ($) & NO. OF UNITS SOLD(2022)
      • TABLE 146     PRODUCT APPROVALS (2021 - 2022)
      • TABLE 147     ACQUISITIONS (2021 - 2022)
      • TABLE 148     PRODUCT LAUNCH (2021 - 2022)
      • TABLE 149     INVESTMENT AND FUNDING (2021 - 2022)
      • TABLE 150     OTHER DEVELOPMENTS (2021 - 2022)
      • TABLE 151     ABBOTT, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q3) ($MN)
      • TABLE 152     ABBOTT, INC.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022)(Q3) ($MN)
      • TABLE 153     ABBOTT, INC.: MEDICAL DEVICES SEGMENT REVENUE, BASED ON SUB-SEGMENT, (2020-2022)(Q3) ($MN)
      • TABLE 154     ABBOTT, INC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022)(Q3) ($MN)
      • TABLE 155     ABIOMED: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q2) ($MN)
      • TABLE 156     ABIOMED: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
      • TABLE 157     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q3)) ($MN)
      • TABLE 158     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022)(Q3) ($MN)
      • TABLE 159     BOSTON SCIENTIFIC CORP.: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENT, (2020-2022)(Q3) ($MN)
      • TABLE 160     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q3)) ($MN)
      • TABLE 161     EDWARDS LIFESCIENCE: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q3)) ($MN)
      • TABLE 162     EDWARDS LIFESCIENCE: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022(Q3)) ($MN)
      • TABLE 163     EDWARDS LIFE SCIENCE: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q3)) ($MN)
      • TABLE 164     GETINGE: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q3)) ($MN)
      • TABLE 165     GETINGE: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022(Q3)) ($MN)
      • TABLE 166     GETINGE: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022(Q3)) ($MN)
      • TABLE 167     MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q2) ($MN)
      • TABLE 168     MEDTRONIC, PLC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022)(Q2) ($MN)
      • TABLE 169     MEDTRONIC, PLC: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2022-2022)(Q2) ($MN)
      • TABLE 170     MEDTRONIC, PLC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2021-2023)(Q2) ($MN)
      • TABLE 171     MICROPORT SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) ($MN)
      • TABLE 172     MICROPORT SCIENTIFIFC CORPORATION: TOTAL REVENUE, BASED ON SEGMENTS, (2019-2021) ($MN)
      • TABLE 173     MICROPORT SCIENTIFIFC CORPORATION TOTAL REVENUE, BASED ON GEOGRAPHY, (2019-2021) ($MN)
      • TABLE 174     TELEFLEX, INC.,: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q3) ($MN)
      • TABLE 175     TELEFLEX, INC.,: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022)(Q3) ($MN)
      • TABLE 176     TELEFLEX, INC.,: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022)(Q3) ($MN)

      LIST OF FIGURES

      • FIGURE 1     HEART FAILURE DEVICES GLOBAL MARKET REVENUE AND SHARE, BASED ON REGION (2021-2029) ($MN) (%)
      • FIGURE 2     RESEARCH METHODOLOGY: HEART FAILURE DEVICES GLOBAL MARKET
      • FIGURE 3     HEART FAILURE DEVICES GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     HEART FAILURE DEVICES GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     HEART FAILURE DEVICES GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     HEART FAILURE DEVICES GLOBAL MARKET SEGMENTATION
      • FIGURE 7     PRODUCTS MARKET SEGMENTATION
      • FIGURE 8     MARKET DYNAMICS
      • FIGURE 9     HEART FAILURE DEVICES GLOBAL MARKET: PORTER'S ANALYSIS
      • FIGURE 10     CARDIAC ASSIST DEVICES MARKET: PATENT FILING BY MAJOR PLAYERS (2018-2022)
      • FIGURE 11     HEART VALVE DEVICES MARKET: PATENT FILING BY MAJOR PLAYERS (2018-2022)
      • FIGURE 12     VENTRICULAR ASSIST DEVICES MARKET: PATENT FILING BY MAJOR PLAYERS (2018-2022)
      • FIGURE 13     HEART FAILURE DEVICES GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 14     HEART FAILURE DEVICES GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 15     VENTRICULAR ASSIST DEVICES (VAD) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 16     INTRA-AORTIC BALLOON PUMP (IABP) GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 17     CARDIAC RESYNCHRONIZATION THERAPY GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, (2022) (%)
      • FIGURE 18     IMPLANTABLE CARDIOVERTER DEFIBRILLATORS GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 19     SINGLE-CHAMBER IMPLANTABLE CARDIOVERTER DEFIBRILLATORS GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 20     DUAL-CHAMBER IMPLANTABLE CARDIOVERTER DEFIBRILLATORS GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 21     PACEMAKER GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 22     SINGLE CHAMBER PACEMAKERGLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 23     DUAL CHAMBER PACEMAKERGLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 24     ANNULOPLASTY REPAIR DEVICES GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 25     OCCLUDERS GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 26     MECHANICAL HEART VALVE GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 27     U.S. PVAD MARKET PENETRATION, (2022) (%)
      • FIGURE 28     ITALY PVAD MARKET PENETRATION, (2022) (%)
      • FIGURE 29     GERMANY PVAD MARKET PENETRATION, (2022) (%)
      • FIGURE 30     FRANCE PVAD MARKET PENETRATION, (2022) (%)
      • FIGURE 31     JAPAN PVAD MARKET PENETRATION, (2022) (%)
      • FIGURE 32     U.S. IABP TAM & MARKET PENETRATION, (2022) (%)
      • FIGURE 33     ITALY IABP TAM & MARKET PENETRATION, (2022) (%)
      • FIGURE 34     GERMANY IABP TAM & MARKET PENETRATION, (2022) (%)
      • FIGURE 35     FRANCE IABP TAM & MARKET PENETRATION, (2022) (%)
      • FIGURE 36     JAPAN IABP TAM & MARKET PENETRATION, (2022) (%)
      • FIGURE 37     GLOBAL TAVR TAM, MARKET PENETRATION, AND NUMBER OF PROCEDURES PERFORMED, (2022)
      • FIGURE 38     U.S. TAVR TAM, MARKET PENETRATION, AND NUMBER OF PROCEDURES PERFORMED, (2022)
      • FIGURE 39     CHINA TAVR TAM, MARKET PENETRATION, AND NUMBER OF PROCEDURES PERFORMED, (2022)
      • FIGURE 40     GLOBAL TMVR AND TMVR TAM, MARKET PENETRATION, AND NUMBER OF PROCEDURES PERFORMED, (2022)
      • FIGURE 41     GLOBAL TPVR TAM, MARKET PENETRATION, AND NUMBER OF PROCEDURES PERFORMED, (2022)
      • FIGURE 42     U.S. BAT MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2022)
      • FIGURE 43     5 E.U. COUNTRIES BAT MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2022)
      • FIGURE 44     5 APAC COUNTRIES BAT MARKET PENETRATION, AND OPPORTUNITY, (2022)
      • FIGURE 45     HEART FAILURE DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT, (2022 VS 2029) (%)
      • FIGURE 46     CARDIAC RHYTHM PRODUCTS GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 47     ICD GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 48     PACEMAKER GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 49     NYHA CLASSIFICATION I II, DEVICE-BASED FLOW CHART FOR PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
      • FIGURE 50     NYHA CLASSIFICATION III, DEVICE-BASED FLOW CHART FOR PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
      • FIGURE 51     NYHA CLASSIFICATION IV, DEVICE-BASED FLOW CHART FOR PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
      • FIGURE 52     CAD GLOBAL MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 53     VAD GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 54     STRUCTURAL HEART DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 55     STRUCTURAL HEART REPAIR DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022) (%)
      • FIGURE 56     TMVR GLOBAL MARKET SHARE, BASED ON REGION, (2022 VS 2029) (%)
      • FIGURE 57     REPLACEMENT DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
      • FIGURE 58     SURGICAL VALVE REPLACEMENT DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
      • FIGURE 59     TRANSCATHETER VALVE REPLACEMENT DEVICES GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
      • FIGURE 60     HEART FAILURE DEVICES GLOBAL MARKET SHARE, BASED ON SURGERY (2022 VS 2029) (%)
      • FIGURE 61     OPEN SURGERY GLOBAL MARKET SHARE, BASED ON REGION, (2022 VS 2029) (%)
      • FIGURE 62     HEART FAILURE DEVICES GLOBAL MARKET SHARE, BASED ON END-USERS (2022 VS 2029) (%)
      • FIGURE 63     HOSPITALS GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
      • FIGURE 64     HEART FAILURE DEVICES GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN), CAGR (%)
      • FIGURE 65     HEART FAILURE DEVICES GLOBAL MARKET SHARE BASED ON REGION AND MARKET REVENUE BY COUNTRY, (2022) (%) ($MN)
      • FIGURE 66     NORTH AMERICA HEART FAILURE DEVICES MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 67     NORTH AMERICA CARDIAC RHYTHM PRODUCTS AND CRT MARKET REVENUE, BASED ON PRODUCT, (2022) ($MN)
      • FIGURE 68     NORTH AMERICA ICD MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 69     NORTH AMERICA PACEMAKER MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 70     NORTH AMERICA CAD MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 71     NORTH AMERICA VAD MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
      • FIGURE 72     NORTH AMERICA SHD MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 73     NORTH AMERICA REPAIR DEVICES MARKET SHARE, BASED ON PRODUCT TYPE, (2022) (%)
      • FIGURE 74     NORTH AMERICA REPLACEMENT DEVICES MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
      • FIGURE 75     NORTH AMERICA SURGICAL VALVE MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
      • FIGURE 76     NORTH AMERICA TRANSCATHETER VALVE MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 77     NORTH AMERICA HEART FAILURE DEVICES MARKET SHARE, BASED ON END-USERS, (2022 VS 2029) (%)
      • FIGURE 78     NORTH AMERICA HEART FAILURE DEVICES MARKET SHARE, BASED ON SURGERY, (2022 VS 2029) (%)
      • FIGURE 79     NORTH AMERICA HEART FAILURE DEVICES MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
      • FIGURE 80     U.S. HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS BASED ON PRODUCT TYPE (2022 VS 2029) ($MN)
      • FIGURE 81     U.S. CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 82     U.S. HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) ($MN)
      • FIGURE 83     THE REST OF THE NORTH AMERICA HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) ($MN)
      • FIGURE 84     REST OF NORTH AMERICA CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 85     REST OF NORTH AMERICA HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) ($MN)
      • FIGURE 86     EUROPE HEART FAILURE DEVICES MARKET SHARE, BASED ON PRODUCT (2022 VS 2029) (%)
      • FIGURE 87     EUROPE CARDIAC RHYTHM PRODUCTS AND CRT MARKET REVENUE, BASED ON PRODUCT, (2022) ($MN)
      • FIGURE 88     EUROPE ICD MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 89     EUROPE PACEMAKER MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 90     EUROPE CAD MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 91     EUROPE VAD MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
      • FIGURE 92     EUROPE SHD MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 93     EUROPE REPAIR DEVICES MARKET SHARE, BASED ON PRODUCT TYPE, (2022) (%)
      • FIGURE 94     EUROPE REPLACEMENT DEVICES MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
      • FIGURE 95     EUROPE SURGICAL VALVE MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
      • FIGURE 96     EUROPE TRANSCATHETER VALVE MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 97     EUROPE HEART FAILURE DEVICES MARKET SHARE, BASED ON END-USERS, (2022 VS 2029) (%)
      • FIGURE 98     EUROPE HEART FAILURE DEVICES MARKET SHARE, BASED ON END-USERS, (2022 VS 2029) (%)
      • FIGURE 99     EUROPE HEART FAILURE DEVICES MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
      • FIGURE 100     GERMANY HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) ($MN)
      • FIGURE 101     GERMANY CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 102     GERMANY HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) ($MN)
      • FIGURE 103     FRANCE HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) ($MN)
      • FIGURE 104     FRANCE CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 105     FRANCE HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) ($MN)
      • FIGURE 106     ITALY HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) ($MN)
      • FIGURE 107     ITALY CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 108     ITALY HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) ($MN)
      • FIGURE 109     REST OF EUROPE HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) ($MN)
      • FIGURE 110     REST OF EUROPE CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 111     REST OF EUROPE HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) ($MN)
      • FIGURE 112     APAC HEART FAILURE DEVICES MARKET SHARE, BASED ON PRODUCT (2022 VS 2029) (%)
      • FIGURE 113     APAC CARDIAC RHYTHM PRODUCTS AND CRT MARKET REVENUE, BASED ON PRODUCT, (2022) ($MN)
      • FIGURE 114     APAC ICD MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 115     APAC PACEMAKER MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 116     APAC CAD MARKET SHARE, BASED ON PRODUCTS, (2022 VS 2029) (%)
      • FIGURE 117     APAC VAD MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
      • FIGURE 118     APAC SHD MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 119     APAC REPAIR DEVICES MARKET SHARE, BASED ON PRODUCT TYPE, (2022) (%)
      • FIGURE 120     APAC REPLACEMENT DEVICES MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
      • FIGURE 121     APAC SURGICAL VALVE MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
      • FIGURE 122     APAC TRANSCATHETER VALVE MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 123     APAC HEART FAILURE DEVICES MARKET SHARE, BASED ON END-USERS, (2022 VS 2029) (%)
      • FIGURE 124     APAC HEART FAILURE DEVICES MARKET SHARE, BASED ON SURGERY, (2022 VS 2029) (%)
      • FIGURE 125     APAC HEART FAILURE DEVICES MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
      • FIGURE 126     JAPAN HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) ($MN)
      • FIGURE 127     JAPAN CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 128     JAPAN HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) ($MN)
      • FIGURE 129     CHINA HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) ($MN)
      • FIGURE 130     CHINA CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 131     CHINA HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) ($MN)
      • FIGURE 132     INDIA HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) ($MN)
      • FIGURE 133     INDIA CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 134     INDIA HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) ($MN)
      • FIGURE 135     REST OF APAC FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) ($MN)
      • FIGURE 136     REST OF APAC CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 137     REST OF APAC HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) ($MN)
      • FIGURE 138     ROW HEART FAILURE DEVICES MARKET SHARE, BASED ON PRODUCT (2022 VS 2029) (%)
      • FIGURE 139     ROW CARDIAC RHYTHM PRODUCTS AND CRT MARKET REVENUE, BASED ON PRODUCT TYPE, (2022) ($MN)
      • FIGURE 140     ROW ICD MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 141     ROW PACEMAKER MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 142     ROW CAD MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 143     ROW VAD MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
      • FIGURE 144     ROW SHD MARKET SHARE, BASED ON PRODUCTS (2022 VS 2029) (%)
      • FIGURE 145     ROW REPAIR DEVICES MARKET SHARE, BASED ON PRODUCT TYPE, (2022) ($MN)
      • FIGURE 146     ROW REPLACEMENT DEVICES MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
      • FIGURE 147     ROW SURGICAL VALVE REPLACEMENT MARKET SHARE, BASED ON PRODUCT TYPE, (2022 VS 2029) (%)
      • FIGURE 148     ROW TRANSCATHETER VALVE MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 149     ROW HEART FAILURE DEVICES MARKET SHARE, BASED ON END-USERS, (2022 VS 2029) (%)
      • FIGURE 150     ROW HEART FAILURE DEVICES MARKET SHARE, BASED ON END-USERS, (2022 VS 2029) (%)
      • FIGURE 151     ROW HEART FAILURE DEVICES MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
      • FIGURE 152     BRAZIL HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) ($MN)
      • FIGURE 153     BRAZIL CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 154     BRAZIL HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) ($MN)
      • FIGURE 155     REST OF LATAM HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) ($MN)
      • FIGURE 156     REST OF LATAM CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 157     REST OF LATAM HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) ($MN)
      • FIGURE 158     MIDDLE EAST AND AFRICA HEART FAILURE DEVICES MARKET REVENUE, BASED ON PRODUCTS & CARDIAC RHYTHM PRODUCTS, BASED ON PRODUCT TYPE (2022 VS 2029) ($MN)
      • FIGURE 159     MIDDLE EAST AND AFRICA CAD & SHD MARKET REVENUE, BASED ON PRODUCTS (2022 VS 2029) ($MN)
      • FIGURE 160     MIDDLE EAST AND AFRICA HEART FAILURE DEVICES MARKET REVENUE, BASED ON END-USER & SURGERY (2022 VS 2029) ($MN)
      • FIGURE 161     KEY GROWTH STRATEGIES, (2021-2022)
      • FIGURE 162     SWOT: ABBOTT, INC.
      • FIGURE 163     SWOT: ABIOMED
      • FIGURE 164     SWOT: BIOTRONIK
      • FIGURE 165     SWOT: BOSTON SCIENTIFIC CORPORATION
      • FIGURE 166     SWOT: CORCYM
      • FIGURE 167     SWOT: EDWARDS LIFESCIENCES
      • FIGURE 168     SWOT: GETINGE
      • FIGURE 169     SWOT: MEDTRONIC, PLC
      • FIGURE 170     SWOT: MICROPORT SCIENTIFIFC CORPORATION
      • FIGURE 171     SWOT: TELEFLEX

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     Abbott Laboratories (U.S.)
      • 2     Abiomed, Inc. (U.S.)
      • 3     Affluent Medical SA (France)
      • 4     AtriCure, Inc. (U.S.)
      • 5     Artivion (Cryolife) (U.S.)
      • 6     Balton Sp. z o.o (Poland)
      • 7     Berlin Heart GmbH (Germany)
      • 8     Biosensor International (NVT AG) (Singapore)
      • 9     BioStable Science & Engineering, Inc. (U.S.)
      • 10     Biotronik (Germany)
      • 11     BiVacor, Inc (U.S.)
      • 12     Bioventrix Inc. (U.S.)
      • 13     Boston Scientific Corporation (U.S.)
      • 14     Braile Biomedica (Brazil)
      • 15     Cardia Inc. (U.S.)
      • 16     Cardiac Dimensions, Inc. (U.S.)
      • 17     CardioBridge GmbH (Germany)
      • 18     CardioDyme (Reliant Heart) (U.S.)
      • 19     Cardiosolutions, Inc. (U.S.)
      • 20     Carmat SA (France)
      • 21     Colibri Heart Valve LLC (U.S.)
      • 22     Corcym (U.K.)
      • 23     Coroneo (Mexico)
      • 24     Corvia Medical (U.S.)
      • 25     CorWave S.A. (France)
      • 26     CVRx (U.S.)
      • 27     Edwards Lifesciences Corporation (U.S.)
      • 28     Evaheart, Inc. (U.S.)
      • 29     FOC Medical S.A. (Argentina)
      • 30     Fresenius Medical Care AG & Co. KGaA (Xenios AG) (Germany)
      • 31     Genesee BioMedical, Inc. (U.S.)
      • 32     Genesis Medtech (JC Medical) (Singapore)
      • 33     Getinge AB (Maquet Holding) (Sweden)
      • 34     Hanyu medical (China)
      • 35     HighLife SAS (France)
      • 36     Impulse Dynamics (Germany)
      • 37     Jarvik Heart, Inc. (U.S.)
      • 38     Jena Valve Technology, Inc, (U.S.)
      • 39     Labcor Laboratorios Ltda (Brazil)
      • 40     Lepu Medical (China)
      • 41     Lifetech Scientific (Shenzhen) Co., Ltd. (China)
      • 42     LivaNova PLC (U.K.)
      • 43     Medico SPA (Italy)
      • 44     Medtronic, PLC (Ireland)
      • 45     Meril Life Sciences Pvt. Ltd. (India)
      • 46     Micro Interventional Devices, Inc. (U.S.)
      • 47     MicroPort Scientific Corporation (China)
      • 48     MiTiHeart Corporation (U.S.)
      • 49     MitrAssist Ltd (Israel)
      • 50     NeoChord, Inc. (U.S.)
      • 51     NeoVasc Inc. (Canada)
      • 52     Occlutech International AB (Sweden)
      • 53     P+F Products + Features GmbH (Germany)
      • 54     Peijia Medical Limited (China)
      • 55     pfm Medical Ag (Germany)
      • 56     Pulse Cath BV (The Netherlands)
      • 57     Sahajanand Medical Technologies Ltd. (India)
      • 58     Senko Medical Instrument Mfg. CO., LTD (Japan)
      • 59     SynCardia Systems, LLC (U.S.)
      • 60     Strait Access Technologies (South Africa)
      • 61     Teleflex Incorporated (U.S.)
      • 62     Thubrikar Aortic Valve, Inc. (U.S.)
      • 63     TTK Healthcare Limited (TTK Chitra Group) (India)
      • 64     Venus Medtech (China)
      • 65     V-Wave Ltd (Israel)
      • 66     Vesalius Cardiovascular Inc. (Canada)
      • 67     W. L. Gore & Associates, Inc. (U.S.)
      • 68     Windmill Cardiovascular systems, Inc. (U.S.)
      • 69     Xeltis (The Netherlands)
      • 70     Xuzhou Yatai Scientific Co., Ltd (China)
      • 71     Zeon Corporation (Japan)